A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer
Phase 1
Active, not recruiting
- Conditions
- Metastatic Solid TumorSolid TumorAdvanced Cancer
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Tachyon Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05076552
- Locations
- 🇺🇸
UCI Health, Orange, California, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸NEXT Oncology, Fairfax, Virginia, United States
© Copyright 2025. All Rights Reserved by MedPath